Nervive’s core ingredient, alpha-lipoic acid (ALA) at 600 mg per tablet, has not been linked to kidney damage in clinical research. In fact, animal and early human studies suggest ALA may actually protect the kidneys rather than harm them. That said, “safe for kidneys” depends heavily on your starting point: a person with healthy kidney function faces different considerations than someone already living with chronic kidney disease. The details behind each ingredient, the supplement’s regulatory status, and a handful of uncommon but real side effects are worth understanding before you commit to daily use.
What Is Actually in Nervive
Nervive’s main product line includes Nerve Relief and Nerve Relief PM, both built around 600 mg of alpha-lipoic acid. The PM version adds 2 mg of melatonin for sleep support. Both formulas also contain thiamine (vitamin B1), which supports normal nervous system function. The manufacturer states that results for neuropathic pain relief begin within about two weeks of daily use.
None of these ingredients are exotic. ALA is a naturally occurring antioxidant found in foods like spinach and organ meats. Thiamine is one of the most common B vitamins, found in grains and legumes. Melatonin is a hormone your body already produces. Still, “natural” does not automatically mean “harmless at supplemental doses,” and each ingredient deserves its own look through the lens of kidney safety.
Alpha-Lipoic Acid and the Kidneys
The bulk of kidney-related research on ALA is reassuring and, in some cases, genuinely encouraging. A 2023 review in Nutrients examined ALA across multiple animal models of kidney injury, including diabetic nephropathy, sepsis-induced injury, and damage from drugs like cisplatin. The consistent finding was that ALA reduced oxidative damage, boosted antioxidant defenses, and lessened both inflammation and kidney scarring.1PubMed Central. Renal-Protective Roles of Lipoic Acid in Kidney Disease A separate review described ALA as showing “clinical promise” in managing kidney diseases through these protective mechanisms.2PubMed Central. Alpha-lipoic acid: A promising pharmacotherapy seen through the lens of kidney diseases
In diabetic animal models specifically, ALA has reduced albuminuria, which is the leakage of protein into urine and one of the earliest signs of kidney trouble. One study in diabetic rats found that ALA cut albuminuria by roughly a third compared to untreated diabetic animals, and it also reduced glomerulosclerosis, a type of scarring in the kidney’s filtering units.3PubMed. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney Another study confirmed that ALA prevented the increase in oxidative stress markers seen in early diabetic kidney tissue.4PubMed. Early oxidative stress in the diabetic kidney: effect of DL-alpha-lipoic acid
There is even a small human trial worth noting. In the QUALITY study, diabetic patients with stage I hypertension who took ALA alongside the blood pressure drug quinapril saw their 24-hour urinary albumin drop by about 53%, compared to a 30% drop in the group taking quinapril alone.5PubMed. The impact of lipoic acid on endothelial function and proteinuria in quinapril-treated diabetic patients with stage I hypertension: results from the QUALITY study That is a meaningful difference, though this was a single small trial, so it is best understood as a promising signal rather than proof.
The important caveat: most of this evidence comes from animal studies or small clinical trials, not large-scale human research. The direction of the evidence is consistently favorable, but no major clinical guideline has endorsed ALA specifically for kidney protection. There is a real gap between “no evidence of harm” and “proven safe for everyone’s kidneys,” and ALA sits in that gap.
ALA’s Actual Side Effects
If ALA’s kidney profile is reassuring, its other side effects are where the story gets more nuanced. The most common complaints at the 600 mg dose used in Nervive are gastrointestinal: nausea, stomach discomfort, and occasional diarrhea. These are usually mild and tend to fade after the first week or two.
A more unusual side effect was documented in an elderly tolerability study: about three quarters of participants noticed a change in urine odor at some point while taking high-dose ALA.6PubMed Central. Tolerability in the elderly population of high-dose alpha lipoic acid: a potential antioxidant therapy for the eye This is harmless but can be alarming if you are not expecting it, especially if you are already worried about kidney health and interpret unusual urine as a danger sign. It is not; it simply reflects how the body metabolizes and excretes ALA.
The rarer and more serious concern involves blood sugar. ALA can lower blood glucose, which is generally mild but occasionally dramatic. Case reports have described a condition called insulin autoimmune syndrome (IAS), where ALA triggers the body to produce antibodies against its own insulin. This leads to unpredictable, sometimes severe episodes of low blood sugar. One case involved a woman who developed markedly elevated insulin autoantibodies after taking ALA supplements; the condition resolved after she stopped taking them.7PubMed Central. Autoimmune hypoglycaemia caused by alpha-lipoic acid: a rare condition in Caucasian patients Another report documented a similar pattern in a non-diabetic patient.8The Egyptian Journal of Internal Medicine. Alpha-lipoic acid induced insulin autoimmune antibody syndrome
IAS from ALA is rare, particularly outside of East Asian populations where certain genetic variants increase susceptibility. But if you are already taking insulin or other diabetes medications, the blood-sugar-lowering effect of ALA is worth discussing with your doctor, because the combination could push glucose dangerously low.
Thiamine and Kidney Health
Nervive’s thiamine (vitamin B1) component is among the least controversial supplements from a kidney perspective. Thiamine is water-soluble, meaning your body excretes excess amounts in urine rather than storing them. There is no well-documented pattern of thiamine causing kidney damage at supplemental doses.
If anything, the research on thiamine and kidneys runs in the protective direction, similar to ALA. A study in diabetic animals found that high-dose thiamine strongly inhibited the development of microalbuminuria, one of the earliest markers of diabetic kidney disease. The mechanism involved reducing protein glycation and oxidative stress.9PubMed. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine
However, when researchers tested benfotiamine (a fat-soluble derivative of thiamine) in a human clinical trial involving patients with diabetic nephropathy, the supplement had no significant effect on markers of endothelial dysfunction, inflammation, or advanced glycation endproducts.10PLoS ONE. Effect of Benfotiamine on Advanced Glycation Endproducts and Markers of Endothelial Dysfunction and Inflammation in Diabetic Nephropathy That is a familiar pattern in supplement research: promising animal data that does not always translate to humans. For kidney safety purposes, though, the relevant takeaway is straightforward. Even in the human trial where benfotiamine did not help, it did not hurt either.
What About Vitamin B6 and Kidney Stones
Some Nervive formulations include vitamin B6, which raises a common question: can B vitamins contribute to kidney stones? A pooled analysis of three large cohort studies found no association between vitamin B6 intake and the risk of developing kidney stones. Comparing the highest intake category to the lowest, the pooled adjusted hazard ratio was 1.03, which is statistically indistinguishable from no effect at all.11PubMed Central. Vitamin B6 Intake and the Risk of Incident Kidney Stones So B6 at typical supplemental doses appears to be a non-issue for stone risk. The vitamin that does raise stone concerns is vitamin C at very high doses (above 1,000 mg per day), which is not a Nervive ingredient.
When Kidney Function Is Already Impaired
Everything discussed so far assumes relatively healthy kidneys. If you are living with chronic kidney disease, the equation shifts. Impaired kidneys clear substances more slowly, which means water-soluble vitamins and their metabolites can accumulate to higher-than-intended levels. A review of vitamin supplementation in CKD noted that while B vitamins and others show promise, “recommendations are still ambiguous, especially in the case of vitamins A and K, due to the potential toxicity associated with higher doses for patients.”12PubMed Central. Does Vitamin Supplementation Play a Role in Chronic Kidney Disease?
For people on dialysis, the problem is twofold. Dialysis strips out water-soluble vitamins non-selectively during each session, which can cause deficiencies. At the same time, vitamins that depend on the kidneys for metabolism and excretion may accumulate to toxic levels between sessions.13PubMed Central. Vitamins in dialysis: who, when and how much? This creates a narrow therapeutic window where supplementation might simultaneously be necessary and risky. ALA has not been specifically studied in dialysis populations in any large trial, which is reason enough to involve a nephrologist before adding Nervive to your routine if you are on dialysis or have stage 3+ CKD.
The melatonin in Nervive PM adds another wrinkle for people with reduced kidney function. Melatonin is primarily metabolized by the liver, so impaired kidneys are less of a concern for clearance. But melatonin can affect blood pressure and interact with medications commonly prescribed in CKD, so it still merits a conversation with your care team.
The Supplement Regulation Problem
A broader kidney safety concern that applies to Nervive and every other dietary supplement in the United States is the regulatory gap. The FDA does not require supplement manufacturers to prove safety and efficacy before selling a product.14Clinical Journal of the American Society of Nephrology. A Review of Dietary Supplement–Induced Renal Dysfunction That does not mean Nervive is unsafe. It means the safety assurances come from the manufacturer and from published research on the individual ingredients, not from the rigorous premarket testing that prescription drugs undergo.
One practical consequence of this gap is the risk of contaminants. A study analyzing 277 dietary supplement products found that while the average daily intake of heavy metals like cadmium, lead, and arsenic was well within acceptable limits, about 1% of products exceeded the acceptable daily intake for at least one heavy metal.15PubMed Central. Heavy Metal contamination of Dietary Supplements products available in the UAE markets and the associated risk Heavy metals are cumulative kidney toxins, so even low-level chronic exposure matters. Choosing supplements from manufacturers who use third-party testing (look for USP, NSF, or ConsumerLab seals) reduces this risk substantially.
A more dramatic example of supplement-related kidney injury involved a Japanese lipid-lowering supplement containing beni-koji (red yeast rice), which caused acute proximal tubular injury and Fanconi syndrome in multiple patients.16PubMed Central. Fanconi syndrome with acute proximal tubular injury induced by a dietary supplement containing beni-koji: a case series report This was not an ALA product and the culprit was likely a contaminant or unexpected metabolite in the red yeast rice, but it illustrates why “dietary supplement” as a category deserves healthy skepticism. The ingredients listed on the label may be fine, but what else is in the bottle matters too.
Nervive Versus Prescription Options for Neuropathy
If you are weighing Nervive against prescription neuropathy medications, the kidney considerations are different. The two most commonly prescribed drugs for neuropathic pain, gabapentin and pregabalin, are primarily eliminated through the kidneys. Pregabalin is excreted largely unchanged in urine, and gabapentin requires dose adjustments in people with impaired kidney function.17PubMed Central. Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety This means that for someone with reduced kidney function, these prescription options require careful dosing and monitoring to avoid accumulation and side effects like sedation and dizziness.
ALA, by contrast, is metabolized primarily by the liver and does not depend on the kidneys for elimination in the same way. That is an advantage in theory for people with mild-to-moderate kidney impairment, though it is not a reason to self-prescribe Nervive as a substitute for medically supervised treatment. Prescription neuropathy medications have undergone large clinical trials establishing their effectiveness, while ALA’s evidence base for pain relief, though positive, is thinner. The kidney-friendliness of ALA’s metabolism is one factor in a much larger decision about which treatment approach makes sense for your situation.
Drug Interactions That Affect the Kidneys Indirectly
ALA interacts with several classes of medications in ways that could indirectly affect kidney health. Its blood-sugar-lowering effect can compound with insulin and oral diabetes drugs, potentially causing hypoglycemia severe enough to require medical attention. Episodes of severe hypoglycemia stress the cardiovascular system and can reduce blood flow to the kidneys, so this is not just an abstract concern.
ALA may also enhance the effects of certain thyroid medications, requiring dose adjustments. And because ALA has mild chelating properties, meaning it binds to metal ions, it could theoretically interfere with the absorption of iron or other mineral supplements. None of these interactions are kidney-toxic in a direct sense, but they can create downstream problems in people who are already managing complex conditions with multiple medications. If you are on more than a couple of prescriptions, run Nervive past your pharmacist. Their drug-interaction databases catch combinations that individual product labels do not flag.
Who Should Be Most Cautious
Pulling the threads together, a few groups should approach Nervive with extra care:
- People with CKD stage 3 or higher: Reduced clearance changes how your body handles any supplement, and ALA has not been studied in this population with enough rigor to know the right dose or the real risk profile.
- Dialysis patients: The push and pull between intradialytic vitamin loss and impaired excretion between sessions makes any supplement a balancing act that your nephrologist needs to manage.
- People on insulin or sulfonylureas: The additive blood-sugar-lowering effect of ALA is real and occasionally dangerous. Monitoring is essential.
- Anyone with a history of insulin autoimmune syndrome: ALA has triggered IAS in case reports, and re-exposure would be unwise.
For people with healthy kidneys and no diabetes medications, Nervive’s ingredient profile carries no known kidney risk at the labeled doses. The 600 mg ALA dose matches what has been used in clinical trials for diabetic neuropathy, and the B vitamins are at conventional supplemental levels. The main practical risk is spending money on a product that may or may not relieve your nerve pain, since the evidence for ALA in neuropathy is moderate rather than strong, and supplement-grade evidence is not held to the same standard as prescription drug evidence.
Urine Changes and False Alarms
One last detail that matters practically: if you start taking Nervive and notice your urine smells different, do not panic. As noted earlier, roughly three out of four people in one tolerability study experienced changes in urine odor while taking high-dose ALA.6PubMed Central. Tolerability in the elderly population of high-dose alpha lipoic acid: a potential antioxidant therapy for the eye B vitamins can also turn urine bright yellow. Neither of these indicates kidney damage. But if you notice foamy urine, blood in your urine, or significant changes in urine volume, those are kidney-relevant symptoms that warrant a call to your doctor regardless of whether you are taking supplements.